We show independent prognostic value for CD8+ and CD20+ cell infiltrates, measured by Immunogradient methodology, and the added prognostic value of the tumor growth pattern as IIS—an integrated prognostic biomarker for MSS and MSI CRCs. Here, CD8A is linked to neoplasm.